Rooted in academic excellence, Epistem's inflammation team has developed an extensive knowledge of the field and applied this experience to a portfolio of preclinical models. The team has been routinely performing in vitro and in vivo studies for the drug discovery industry for over 10 years. This comprehensive understanding of the models and assays offered enables Epistem to offer a consultative approach to study design; advice can be provided on selection of the most suitable model, particularly with reference to the performance of therapeutic agents. Epistem offers a range of in vivo disease models reflecting several key areas of autoimmune disease. Supported by a suite of mechanistic assays, these can provide a valuable and comprehensive data package.

Epistem continues to develop innovative and clinically relevant assays and models to support the drug discovery and development pipeline. Most recently a validated, in vitro model of psoriasis, addressing the need for a clinically relevant model within the industry, was added to the portfolio.

Epistem's Immune Cell Services:

Mechanistic Assays